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1. Introduction
Within a Pavlovian drug conditioning framework, research 
on nicotine has focused on its unconditioned stimulus proper-
ties. For example, repeated pairings of a conditional stimulus 
such as a chamber or fl avor with a nicotine unconditioned stim-
ulus can produce a place preference (Fudala et al., 1985, Shoaib 
et al., 1994a and Shoaib et al., 1994b), taste aversion (Iwamoto 
and Williamson, 1984 and Kumar et al., 1983), or conditioned 
hyperactivity (Bevins and Palmatier, 2003, Bevins et al., 2001, 
Bevins et al., 2005, Shoaib et al., 1994a, Shoaib et al., 1994b 
and Walter and Kuschinsky, 1989) in rats. More recently, sys-
temic nicotine has been found to serve as a positive drug fea-
ture (occasion setter) indicating when a discrete light condition-
al stimulus will be followed by brief access to liquid sucrose 
(Bevins and Palmatier, 2004, Palmatier et al., 2004 and Palma-
tier et al., 2005). Nicotine can also cue when a discrete light 
conditional stimulus will not be followed by sucrose, thereby 
serving as a negative drug feature (Bevins et al., 2006).
Nicotine has also recently been shown to serve as an intero-
ceptive contextual conditional stimulus for access to sucrose in 
rats (Besheer et al., 2004 and Wilkinson et al., 2006b). Briefl y, 
in that research, a subcutaneous (s.c.) injection of 0.4 mg base/
kg nicotine or saline was given 5 min before placement in a 
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Abstract
In rats, the pharmacological (interoceptive) effects of 0.4 mg/kg nicotine can serve as a conditional stimulus in a Pavlovian condi-
tioning task. Nicotine administration is paired with intermittent access to a liquid sucrose unconditional stimulus; sucrose is with-
held on saline sessions. An increase in sucrose receptacle entries (goal tracking) on nicotine sessions indicates conditioning. Rats 
were trained on a nicotine dose ((-)-1-Methyl-2-(3-pyridyl)pyrrolidine; 0.1, 0.2, or 0.4 mg base/kg, s.c.). Generalization was exam-
ined using 0.025, 0.05, 0.1, 0.2, and 0.4 mg/kg nicotine and saline. Some behavioral effects of nicotine have been attributed to do-
pamine and glutamate. Accordingly, potential blockade of the nicotine cue via the dopamine system was examined by administering 
(R)-(+)-7-Chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride (SCH-23390; 0.005, 0.01, and 
0.03 mg/kg), 3-Chloro-5-ethyl-N-[[(2S)-1-ethyl-2-pyrrolidinyl)methyl]-6-hydroxy-2-methoxy-benzamide hydrochloride (eticlo-
pride; 0.01, 0.03, 0.1, and 0.3 mg/kg), or N-[(1-Butyl-2-pyrrolidinyl)methyl]-4-cyano-1-methoxy-2-naphthalenecarboxamide (na-
fadotride; 0.03, 0.1, 0.3, 1, and 3 mg/kg) before nicotine. 2-Methyl-6-(phenylethynyl)pyridine hydrochloride (MPEP; 0.3, 1, and 3 
mg/kg) and (5S,10R)-(+)-5-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate (MK-801; 0.01, 0.03, 0.1, and 
0.2 mg/kg; dizocilpine) were used to examine possible glutamatergic components. Substitution tests were conducted with MPEP 
and nafadotride. Differential conditioned responding was acquired in the 3 groups. Conditioned responding generally decreased as 
the nicotine test dose moved away from the training dose; responding increased when 0.4 mg/kg trained rats were tested with 0.2 
mg/kg. SCH-23390, eticlopride, nafadotride, and MPEP decreased conditioned responding on nicotine at doses that also decreased 
chamber activity. In contrast, MK-801 decreased goal tracking on nicotine without decreasing chamber activity, indicating a role for 
N-methyl-D-aspartate receptors in expression of nicotine-evoked conditioned responding. 
Keywords: Classical conditioning, CS, US, Drug discrimination, Nicotinic acetylcholine receptor, NMDA receptor, Interoceptive cue
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conditioning chamber. On nicotine sessions, liquid sucrose was 
delivered intermittently. On intermixed saline sessions, sucrose 
was not available. Using head entries into the sucrose recepta-
cle before the fi rst sucrose delivery as a measure of condition-
ing (i.e., goal tracking; Boakes, 1977 and Farwell and Ayres, 
1979), nicotine readily served as a conditional stimulus as evi-
denced by increased dipper entries on nicotine compared to sa-
line sessions. Importantly, when a group of rats had access to 
sucrose on both nicotine and saline sessions, differential condi-
tioned responding did not develop (Wilkinson et al., 2006b).
The current study sought to extend that research by assess-
ing whether 0.2 and 0.1 mg/kg nicotine can also serve as a con-
ditional stimulus in the same paradigm. To date, initial acquisi-
tion of the discrimination has used 0.4 mg/kg nicotine (Besheer 
et al., 2004 and Wilkinson et al., 2006b). Bevins and Palmati-
er (2004) reported that 0.2 and 0.1 mg/kg nicotine served as a 
conditional stimulus for a sucrose unconditioned stimulus when 
the doses were faded from 0.4 mg/kg. In that research, rats were 
trained as previously described with 0.4 mg/kg nicotine. After 
acquisition, the nicotine conditional stimulus was shifted to 0.2 
mg/kg. Once conditioned responding stabilized, the 0.2 mg/kg 
conditional stimulus was again shifted and subsequently stabi-
lized at 0.1 mg/kg. Because the lower nicotine doses came to 
control nicotine-evoked conditioned responding and because 
each of these nicotine doses are effective discriminative cues in 
the operant conditioning literature without use of a fading pro-
cedure (Chance et al., 1977, Desai et al., 2003, Gasior et al., 
1999, Morrison and Stephenson, 1969, Pratt et al., 1983 and 
Stolerman et al., 1997), we expected 0.2 and 0.1 mg/kg to func-
tion as conditional stimuli even when trained as the initial con-
ditional stimuli for sucrose.
Another purpose of the present study was to begin to eluci-
date the neuropharmacological mechanisms of the nicotine con-
ditional stimulus. Nicotine administration to rats increases do-
pamine release in the nucleus accumbens (Di Chiara and Imper-
ato, 1988, Imperato et al., 1986, Pidoplichko et al., 2004, Pon-
tieri et al., 1996 and Toth et al., 1992). This dopamine release 
is attributed to presynaptic activation of nicotinic acetylcholine 
receptors on ventral tegmental area afferents, as well as direct 
postsynaptic nicotinic acetylcholine receptor activation on do-
paminergic neurons projecting to the nucleus accumbens (Cor-
rigall et al., 1994 and Nisell et al., 1994). Links have been made 
between dopamine receptor function and a variety of nicotine 
effects. For example, SCH-23390 is a dopamine D1 receptor an-
tagonist (Andersen and Grønvald, 1986, Hyttel and Arnt, 1987 
and Iorio et al., 1983) that blocks nicotine-induced increases of 
dopamine in the nucleus accumbens (Sziráki et al., 1998). SCH-
23390 has also been found to block the expression of nicotine-
conditioned hyperactivity without affecting activity in controls 
(Bevins et al., 2001) and to reverse nicotine-induced lowering 
of brain reward thresholds (Harrison et al., 2002). When eticlo-
pride, a dopamine D2/ D3 receptor antagonist (Hall et al., 1985, 
Köhler et al., 1986 and Tang et al., 1994), is infused into the 
ventral tegmental area, nicotine-induced increases in dopamine 
in the nucleus accumbens are partially inhibited (Sziráki et al., 
2002). Dopamine D3 receptor antagonists have been shown to 
block expression of nicotine-conditioned place preference (Le 
Foll et al., 2005) and nicotine-conditioned hyperactivity (Le 
Foll et al., 2003). Although the effects of the dopamine D3 re-
ceptor antagonist nafadotride have not been explicitly studied 
with nicotine, its specifi city in vivo makes it a useful tool for 
studying potential dopamine D3-mediated behaviors (Audinot 
et al., 1998 and Levant and Vansell, 1997). In brief, given the 
clear effects of nicotine on dopamine, we examined the poten-
tial role of dopamine D1, D2, and D3 receptors in mediating nic-
otine’s ability to function as a conditional stimulus.
Nicotine administration also modulates glutamate function. 
Glutamatergic afferents to the ventral tegmental area from the 
prefrontal cortex contain presynaptic nicotinic acetylcholine re-
ceptors that, when activated, increase neurotransmitter release 
(McGehee et al., 1995 and Schilström et al., 2000). Administra-
tion of nicotine increases glutamate levels in the striatum and 
nucleus accumbens relative to saline controls (Reid et al., 2000 
and Toth et al., 1992). Moderate doses of MPEP, a metabotropic 
glutamate receptor type 5 antagonist (Gasparini et al., 1999), 
have been shown to decrease nicotine self-administration in rats 
without affecting responding for food (Kenny et al., 2003 and 
Paterson et al., 2003). MPEP also decreased drug-seeking be-
havior during nicotine- and cue-induced reinstatement of nic-
otine self-administration without affecting food-seeking rein-
statement (Bespalov et al., 2005 and Tessari et al., 2004) show-
ing a role for metabotropic glutamate receptor type 5 activation 
in the rewarding effects of nicotine. Additionally, in an operant 
drug discrimination task using 0.6 mg/kg nicotine as a discrimi-
native stimulus for food reinforcement, MPEP partially blocked 
differential lever pressing controlled by nicotine without affect-
ing response rate (Zakharova et al., 2005). Accordingly, we test-
ed MPEP to examine the role of metabotropic glutamate recep-
tor type 5 activation in the cueing effects of nicotine.
Postsynaptic N-methyl-D-aspartate receptors are only acti-
vated when glutamate binds to its site on the receptor and the 
cell membrane has suffi ciently depolarized to remove Mg2+ 
from blocking the receptor channel, and therefore serve to com-
bine chemical and electrical messaging (Ascher and Nowak, 
1988 and Kiss et al., 1994). Glutamate release via nicotinic ace-
tylcholine receptor stimulation ultimately activates N-methyl-D-
aspartate receptors, increasing ventral tegmental area dopami-
nergic burst fi ring into the nucleus accumbens (Schilström et 
al., 2003 and Schilström et al., 2004). Blockade of N-methyl-
D-aspartate receptors using MK-801, a non-competitive chan-
nel blocker (Amador and Dani, 1991, Halliwell et al., 1989, 
Huettner and Bean, 1988 and Wong et al., 1986) inhibited nico-
tine-induced dopamine release in the nucleus accumbens (Szirá-
ki et al., 1998). MK-801 also attenuated development and ex-
pression of nicotine-induced behavioral sensitization and the 
development of tolerance to the locomotor depressant effects of 
nicotine (Shim et al., 2002, Shoaib et al., 1994a, Shoaib et al., 
1994b, Shoaib et al., 1997 and Shoaib and Stolerman, 1992). 
Due to the apparent role of N-methyl-D-aspartate receptors in 
modulation of behavioral effects of nicotine, we used MK-801 
to determine if N-methyl-D-aspartate receptor activation is in-
volved in nicotine’s ability to serve as a conditional stimulus.
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2. Materials and methods
2.1. Subjects
Twenty-seven male Sprague-Dawley rats (302 ± 17 g at start 
of study) were obtained from Harlan (Indianapolis, IN, USA). 
Rats had previously been used in a brief drug-free study assess-
ing whether exposure to an alternate environment proactively 
interfered with familiarization of a testing environment as in-
dexed by novel object interaction (Wilkinson et al., 2006a). 
Rats were housed individually in clear 48.3 × 26.7 × 20.3 cm 
(l × w × h) polycarbonate tubs lined with aspen shavings. Wa-
ter was continuously available in the home cage. Rats received 
food (Harlan Teklad Rodent Diet) after completion of daily ses-
sions and the quantity was restricted as to maintain rats at 85% 
of free-feeding body weights. Approximately every 4 weeks the 
85% target weight was increased by 2 g. The colony was tem-
perature and humidity controlled. All sessions were conduct-
ed during the light portion of a 12 h light:dark cycle. Protocols 
were approved by the University of Nebraska-Lincoln Animal 
Care and Use Committee and followed the ‘Guide for the Care 
and Use of Laboratory Animals’ (National Research Council, 
1996).
2.2. Apparatus
Eight conditioning chambers (ENV-008CT; Med Associates, 
Inc., St. Albans, VT, USA) measuring 30.5 × 24.1 × 21.0 cm (l 
× w × h) were used in this study. Sidewalls were aluminum; the 
ceiling and front and back walls were clear polycarbonate. Each 
chamber was equipped with a recessed receptacle (5.2 × 5.2 × 
3.8 cm; l × w × d) on one sidewall. A dipper arm raised a 0.1-
ml cup of 26% sucrose solution (w/v) into the receptacle. An 
infrared emitter/detector unit, 1.2 cm into the receptacle and 3 
cm from the chamber fl oor, monitored head entries into the dip-
per. A second infrared emitter/detector unit was added to each 
chamber during the study to provide a measure of general ac-
tivity. This unit bisected the chamber 14.5 cm from the side-
wall containing the receptacle and was positioned 4 cm above 
the rod fl oor. Each chamber was enclosed in a light- and sound-
attenuating cubicle fi tted with a fan to provide airfl ow and mask 
noise. A personal computer with Med Associates interface and 
software (Med-PC for Windows, version IV) controlled sucrose 




1H-3-benzazepine hydrochloride (SCH-23390), and 3-Chlo-
ro-5-ethyl-N-[[(2S)-1-ethyl-2-pyrrolidinyl)methyl]-6-hy-
droxy-2-methoxy-benzamide hydrochloride (eticlopride) were 
purchased from Sigma (St. Louis, MO, USA). 2-Methyl-6-
(phenylethynyl)pyridine hydrochloride (MPEP), (5S,10R)-
(+)-5-Methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-
5,10-imine maleate (MK-801; dizocilpine), and N-[(1-Butyl-2-
pyrrolidinyl)methyl]-4-cyano-1-methoxy-2-naphthalenecarbox-
amide (nafadotride) were purchased from Tocris Cookson, Inc. 
(Ellisville, MO, USA). Nafadotride was dissolved at 100 mM 
in 1 eq. HCl. Distilled water was then added to obtain desired 
concentrations. All other drugs were mixed in 0.9% saline solu-
tion. Nicotine was adjusted to a pH of 7.0 ± 0.2 using a dilute 
NaOH solution and injected s.c. 5 min before placement in the 
chamber. Remaining drugs were injected intraperitoneally (i.p.) 
30 min before testing. All solutions were injected at 1 ml/kg. 
Nicotine doses are reported in the base form; remaining doses 
are salt form.
2.4. Acquisition
Rats were randomly assigned to a training dose (n = 9/dose) 
of nicotine (0.1, 0.2, or 0.4 mg/kg) and handled for at least 3 
min per day for 3 days. Rats were then given an injection of 
their training dose of nicotine for the next 3 days in the home 
cage in order to attenuate the initial locomotor suppressant ef-
fects of nicotine (Besheer et al., 2004 and Bevins et al., 2001). 
Daily training sessions began the day following the last nicotine 
injection. Rats received either nicotine or saline s.c. 5 min be-
fore placement in the chambers for 20 min. During nicotine ses-
sions, there were 36 deliveries of 4-s access to sucrose. In or-
der to discourage timing of sucrose deliveries, 4 different pro-
grams were created. The average time before the fi rst sucrose 
delivery across programs was 137 s with a range of 124-152 s. 
No sucrose was delivered during saline sessions. Session types 
and programs were randomly assigned with the restriction that 
no more than 2 nicotine or 2 saline sessions occurred in a row. 
Training continued for 22 nicotine and 22 saline sessions.
2.5. Testing
Following acquisition of the discrimination, rats entered the 
testing phase. On the fi rst 4 consecutive days of a 5-day cycle, 
rats received 2 nicotine and 2 saline training sessions as de-
scribed earlier. If a rat met the discrimination criterion (see lat-
er), on day 5 a 4-min test session occurred in place of a training 
session; no sucrose was delivered in testing. If the criterion was 
not met, the rat was not tested and remained in its home cage.
2.5.1. Nicotine generalization
On test days, each rat received a dose of nicotine (see Table 
1) or saline injected s.c. 5 min before placement in the cham-
ber for the 4-min test sessions. Rats received the test solutions 
in a random order. Upon completion of the fi rst order, each dose 
was given again in a different random order. Due to the consis-
tent motor ataxia produced by 0.6 mg/kg nicotine, that dose was 
removed from the testing sequence after a few rats had tested 
and was not included in any analysis or fi gure. 
2.5.2. Antagonism and substitution
Following completion of nicotine generalization, testing cy-
cles continued as previously described. Photobeams bisect-
ing the chamber were added at this time to provide a measure 
of general activity. On antagonism test sessions, the antagonist 
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was administered i.p. 30 min before placement in the chamber - 
25 min before injection of the nicotine training dose. Substitu-
tion sessions were similar except nicotine was not administered 
before the test session. Table 1 shows the progression of testing. 
Within each phase, the test doses and saline were randomly in-
termixed. Rats completed all ligands and doses in a phase be-
fore beginning the next phase.
2.6. Dependent measures
The dependent measure for acquisition was the rate of dip-
per entries per s before the fi rst sucrose delivery. In order to 
allow comparable measurement between nicotine (i.e., su-
crose) and saline sessions (i.e., no sucrose), the program types 
were matched for timing of the intervals from which the de-
pendent measure (i.e., dipper entry rate) was taken. A differ-
ence score was then calculated by taking the dipper entry rate 
before the fi rst sucrose delivery on nicotine sessions minus 
the dipper entry rate on corresponding saline sessions. A dif-
ference score of 0 indicates no discrimination. A positive dif-
ference score indicates higher rate of dipper entries on nico-
tine than saline sessions. The dependent measure for test ses-
sions was the dipper entry rate in the fi rst 2 min of the test 
(cf. Besheer et al., 2004). The fi rst 2 min was used to approx-
imate the average time before the fi rst sucrose delivery in nic-
otine training sessions. In antagonism and substitution testing, 
a general activity rate (beam breaks per s in the fi rst 2 min of 
the test) was also analyzed. The testing criterion was that the 
dipper entry rate on each nicotine session was a minimum of 
0.01 entries per s higher than each saline session across the 4 
training days of a testing cycle.
2.7. Data analysis
Difference scores for acquisition were examined using a 2-
way analysis of variance (ANOVA) comparing the nicotine 
training groups (0.1, 0.2, or 0.4 mg/kg) across sessions. To 
more thoroughly examine the discrimination patterns, 2-way 
Fig. 1. Panel A shows the mean difference scores (nicotine dipper entry rate minus saline session dipper entry rate; ± 1 S.E.M.) of discrimi-
nation training for each group. Panels B–D show mean dipper entries per s (± 1 S.E.M.) on nicotine and saline sessions during discrimination 
training for each group. The number of rats per group for acquisition was 9, 9, and 9 for the 0.1, 0.2, and 0.4 mg/kg groups, respectively. de-
notes signifi cant difference between dipper entry rates on corresponding nicotine and saline sessions, P < 0.05. 
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ANOVAs were conducted for each training group to compare 
dipper entry rates on nicotine versus saline across sessions. For 
nicotine generalization, antagonism, and substitution, 2-way 
ANOVAs were used to compare dose of ligand across nicotine 
groups for dipper entry and activity rates. ANOVAs were fol-
lowed by pair-wise comparisons using Fisher’s least signifi cant 
difference (LSD) tests that control for Type I error rate. Median 
effective doses (ED50s) were calculated on the linear portions of 
nicotine generalization curves and antagonists resulting in full 
blockade of conditioned responding. Statistical signifi cance was 
declared using a 2-tailed rejection region of 0.05 for all tests.
3. Results
3.1. Acquisition
Fig. 1A shows the difference scores for each nicotine dose. 
There was a main effect of Session [F(21,483) = 10.21, P < 
0.001], but no main effect of Group [F(2,23) = 2.49, P > 0.05] 
or Group × Session interaction [F < 1]. This pattern indicates 
that the discrimination was acquired at the same pace and to 
a similar degree regardless of nicotine dose. For acquisition of 
each nicotine dose (see Fig. 1B-D), there were signifi cant main 
effects of Type (nicotine versus saline) [Fs ≥ 40.71, Ps < 0.001], 
Session [Fs ≥ 2.22, Ps < 0.01], and Type × Session interactions 
[Fs ≥ 3.36, Ps < 0.001, mean square errors (MSE) ≤ 0.003]. 
For the 0.1 mg/kg group, dipper entry rates were lower on nic-
otine than saline for sessions 3 and 4, and higher for sessions 
6–22 [LSDmimimum mean difference (mmd) = 0.041]. For the 0.2 mg/
kg group, dipper entry rates were higher on nicotine than saline 
for sessions 6–22 [LSDmmd = 0.051]. For the 0.4 mg/kg group, 
there were lower dipper entry rates on nicotine than saline for 
session 1, and higher for sessions 6–22 [LSDmmd = 0.054]. ≤
3.2. Testing
3.2.1. Nicotine generalization
Fig. 2 shows the generalization curves for each training dose 
of nicotine. The mean of the 2 test scores for each rat was used 
for analyses and graphing. A rat trained with 0.4 mg/kg nico-
tine was removed during this phase for failure to maintain the 
discrimination. Although there was no main effect of Group 
[F(2,23) = 294.52, P = 0.062], there was a main effect of Nic-
otine [F(5,115) = 32.81, P < 0.001] and a signifi cant Group 
× Nicotine interaction [F(10,115) = 2.11, P = 0.029, MSE = 
0.002]. For the 0.1 mg/kg group, dipper entry rates for 0.05, 
0.1, and 0.2 mg/kg were higher than saline [LSDmmd = 0.042]. 
Further, dipper entry rates on saline, 0.025, 0.05, and 0.4 mg/
kg were lower than that of the 0.1 mg/kg training dose. For the 
0.2 mg/kg group, dipper entry rates for 0.05, 0.1, and 0.2 mg/
kg were higher than saline; rates for saline, 0.025, 0.05, and 0.4 
mg/kg were lower than the 0.2 mg/kg training dose. For the 0.4 
mg/kg group, dipper entry rates were higher for 0.05, 0.1, 0.2, 
and 0.4 mg/kg than saline; saline and 0.025 mg/kg were low-
er than the training dose. Notably, in rats trained on 0.4 mg/kg, 
goal tracking increased on 0.2 mg/kg relative to the training 
dose. ED50s for the 0.1, 0.2, and 0.4 mg/kg groups were 0.054, 
0.049, and 0.050 mg/kg, respectively. 
3.2.2. MPEP antagonism
Fig. 3A shows the effects of MPEP on dipper entry rates 
for 0.1, 0.2, and 0.4 mg/kg nicotine groups. The ANOVA re-
vealed a main effect of Drug [F(3,69) = 26.97, P < 0.001], but 
no main effect of Group or Drug × Group interaction [Fs < 1, 
MSE = 0.002], indicating that MPEP comparably decreased 
conditioned responding to nicotine regardless of training dose. 
For the 0.1 mg/kg nicotine group, dipper entry rates were low-
Fig. 2. This fi gure shows the mean dipper entry rates (± 1 S.E.M.) of 
nicotine generalization for each group. The number of rats per group 
for generalization was 9, 9, and 8 for the 0.1, 0.2, and 0.4 mg/kg 
groups, respectively. Signifi cant differences and ED50s are reported 
in the text. 
Fig. 3. Panel A shows the mean dipper entry rates (± 1 S.E.M.) of 
MPEP antagonism for each nicotine training group. Panel B shows 
the mean beam break (activity) rates (± 1 S.E.M.) of MPEP antago-
nism for each nicotine training group. The number of rats per group 
for MPEP antagonism was 9, 9, and 8 for the 0.1, 0.2, and 0.4 mg/kg 
groups, respectively. For both panels, signifi cant differences, ED50s, 
and baseline means are reported in the text. 
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er after 1 and 3 mg/kg MPEP than with saline pretreatment [LS-
Dmmd = 0.042]. For the 0.2 and 0.4 mg/kg groups, dipper en-
try rates were lower with 3 mg/kg MPEP pretreatment than sa-
line. Fisher’s LSD tests were also used to compare each group 
to its saline (no nicotine) baseline [Means (Ms) = 0.032 ± 0.006 
for 0.1 mg/kg, 0.021 ± 0.004 for 0.2 mg/kg, and 0.039 ± 0.010 
for 0.4 mg/kg nicotine]. These baselines were generated using 
the last saline session for each rat before testing with 1 mg/kg 
MPEP (cf. Besheer et al., 2004). For all 3 training doses, dipper 
entries after saline, 0.3, and 1 mg/kg MPEP pretreatment were 
higher than respective saline baselines. Only 3 mg/kg MPEP re-
duced dipper entry rates to saline levels. ED50s for the 0.1, 0.2, 
and 0.4 mg/kg groups were 1.64, 1.50, and 1.64 mg/kg MPEP, 
respectively. 
Fig. 3B shows the effects of MPEP antagonism on chamber 
activity for 0.1, 0.2, and 0.4 mg/kg nicotine. Although there was 
no main effect of Group [F(2,23) = 2.67, P = 0.090], there was 
a main effect of Drug [F(3,69) = 31.90, P < 0.001] and a signif-
icant Drug × Group interaction [F(6,69) = 4.24, P < 0.01, MSE 
= 0.009]. For the 0.1 mg/kg nicotine group, activity decreased 
after 3 mg/kg MPEP pretreatment compared with saline [LS-
Dmmd = 0.091]. For the 0.2 mg/kg nicotine group, activity was 
lower after 1 and 3 mg/kg MPEP pretreatment compared with 
saline. Activity for the 0.4 mg/kg nicotine group was also lower 
after 3 mg/kg MPEP pretreatment compared with saline; how-
ever, activity increased after 0.3 and 1 mg/kg MPEP pretreat-
ment for this group.
3.2.3. SCH-23390 and eticlopride antagonism
Fig. 4A shows the mean dipper entry rates for responding on 
nicotine after administration of SCH-23390. There was a main 
effect of Drug [F(3,69) = 13.00, P < 0.001], but no main effect 
of Group or Drug × Group interaction [Fs < 1, MSE = 0.002] 
indicating that SCH-23390 decreased conditioned responding 
to nicotine regardless of training dose. For each training group, 
dipper entry rates decreased after 0.03 mg/kg SCH-23390 pre-
treatment compared to saline [LSDmmd = 0.042]. A saline (no 
nicotine) baseline was generated for SCH-23390 using the 
mean dipper entry rates on the saline session before the 0.005 
mg/kg SCH-23390 test session [Ms = 0.027 ± 0.005, 0.036 ± 
0.009, and 0.036 ± 0.005 for 0.1, 0.2, and 0.4 mg/kg nicotine, 
respectively]. For all groups, conditioned responding was high-
er than the baseline with 0.005 and 0.01 mg/kg SCH-23390 and 
saline pretreatment. Only 0.03 mg/kg SCH-23390 lowered con-
ditioned responding to saline levels. ED50s for 0.1, 0.2, and 0.4 
mg/kg nicotine groups were 0.03, 0.02, and 0.02 mg/kg SCH-
23390, respectively. Activity rates with SCH-23390 pretreat-
ment are shown in Fig. 4B. There was a signifi cant main ef-
fect of Drug [F(3,69) = 19.97, P < 0.001] and Group [F(2,23) 
= 3.69, P = 0.041, MSE = 0.025], but no signifi cant Drug × 
Fig. 4. Panel A shows the mean dipper entry rates (± 1 S.E.M.) of SCH-23390 antagonism for each nicotine training group. Panel B shows 
the mean beam break (activity) rates (± 1 S.E.M.) of SCH-23390 antagonism for each nicotine training group. Panel C shows the mean dip-
per entry rates (± 1 S.E.M.) of eticlopride antagonism for each nicotine training group. Panel D shows the mean beam break (activity) rates (± 
1 S.E.M.) of eticlopride antagonism for each nicotine training group. The number of rats was 9, 9, and 8 for the 0.1, 0.2, and 0.4 mg/kg groups, 
respectively. For all panels, signifi cant differences, ED50s, and baseline means are reported in the text. 
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Group interaction [F < 1, MSE = 0.010]. The 0.4 mg/kg group 
had higher activity than the 0.1 mg/kg group [LSDmmd = 0.055]. 
For each group, activity was lower with 0.03 mg/kg SCH-23390 
than saline pretreatment [LSDmmd = 0.096]. 
Fig. 4C shows the mean dipper entry rates for each group af-
ter eticlopride pretreatment. There was a main effect of Drug 
[F(4,92) = 17.15, P < 0.001], but no effect of Group or Drug × 
Group interaction [Fs < 1, MSE = 0.003]. The 0.1 and 0.2 mg/
kg nicotine had decreased dipper entry rates with 0.3 mg/kg eti-
clopride pretreatment compared with saline pretreatment [LSD-
mmd = 0.052]. For the 0.4 mg/kg group, dipper entry rates were 
lower after 0.1 and 0.3 mg/kg eticlopride than saline pretreat-
ment. The saline baseline described for SCH-23390 was also 
used for eticlopride. The 0.1 and 0.2 mg/kg nicotine-trained 
groups had higher dipper entries after saline, 0.01, 0.03, and 0.1 
mg/kg eticlopride pretreatment than baseline saline levels. For 
the 0.4 mg/kg group, dipper entries after saline, 0.01, and 0.03 
mg/kg eticlopride pretreatment were higher than baseline sa-
line levels. ED50s for 0.1, 0.2, and 0.4 mg/kg nicotine groups 
were 0.15, 0.17, and 0.12 mg/kg eticlopride, respectively. Gen-
eral chamber activity after eticlopride pretreatment is shown in 
Fig. 4D. There was a main effect of Drug [F(4,92) = 14.95, P 
< 0.001] and a main effect of Group [F(2,23) = 3.93, P < 0.05] 
but no Drug × Group interaction [F < 1, MSE = 0.014]. For the 
0.1 and 0.2 mg/kg groups, activity after 0.3 mg/kg eticlopride 
pretreatment was lower than saline [LSDmmd = 0.113]. For the 
0.4 mg/kg group, activity after 0.1 and 0.3 mg/kg eticlopride 
pretreatment was lower than saline.
3.2.4. MPEP substitution
The MPEP substitution phase was conducted to further ex-
plore the increased activity in the 0.4 mg/kg group during 
MPEP antagonism. Fig. 5A shows the effect of MPEP substitu-
tion tests on dipper entries. There was no main effect of Drug, 
Group, or Drug × Group interaction [Fs ≤ 1.70, Ps ≥ 0.188]. 
Conditioned responding on MPEP did not differ from saline, re-
gardless of training dose of nicotine. General activity for MPEP 
substitution is shown in Fig. 5B. There were main effects of 
Drug [F(3,69) = 3.05, P = 0.034] and Group [F(2,23) = 4.08, 
P = 0.030, MSE = 0.031], but no signifi cant Drug × Group in-
teraction [F < 1, MSE = 0.011]. Follow-up comparisons of the 
main effect of Group for general activity rates across tests [Ms 
= 0.189, 0.268, and 0.309 for 0.1, 0.2, and 0.4 mg/kg nicotine, 
respectively] revealed that only the 0.4 mg/kg group was more 
active than the 0.1 mg/kg group, [LSDmmd = 0.088]. Within in-
dividual groups, 3 mg/kg MPEP decreased activity below that 
of saline for the 0.1 mg/kg group, [LSDmmd = 0.10]. For the 0.2 
mg/kg group, 0.3 mg/kg MPEP produced lower general activity 
than saline. There were no MPEP-induced shifts in activity for 
the 0.4 mg/kg group. 
3.2.5. Nafadotride and MK-801 antagonism
A rat in the 0.1 mg/kg group and a rat in the 0.4 mg/kg group 
were removed due to an inability to continue testing. Fig. 6A 
shows the mean dipper entry rates for each group after nafado-
tride pretreatment. There was a main effect of Drug [F(5,105) = 
5.01, P < 0.001], but no main effect of Group [F < 1] or Drug 
× Group interaction [F(10,105) = 1.32, P = 0.23, MSE = 0.002] 
indicating that nafadotride decreased conditioned responding on 
nicotine regardless of training dose. Follow-up analysis of the 
main effect of Drug showed that overall conditioned respond-
ing after 3 mg/kg nafadotride pretreatment was lower than sa-
line pretreatment [LSDmmd = 0.025]. However, within individu-
al groups there were no differences between test doses of nafad-
otride and saline pretreatment [LSDmmd = 0.048]. A saline (no 
nicotine) baseline was generated for nafadotride antagonism us-
ing the mean dipper entry rates on the saline session before the 
0.03 mg/kg MK-801 test session [Ms = 0.028 ± 0.005, 0.036 ± 
0.004, and 0.047 ± 0.010 for 0.1, 0.2, and 0.4 mg/kg nicotine, 
respectively]. For the 0.1 and 0.2 mg/kg groups, responding 
on all tests was higher than the saline baseline. For the 0.4 mg/
kg group, dipper entries after 3 mg/kg nafadotride were sim-
ilar to the saline baseline. General activity rates after nafado-
tride pretreatment are shown in Fig. 6B. There was a main ef-
fect of Drug [F(5,105) = 5.06, P < 0.001], but no main effect of 
Group [F(2,21) = 1.35, P = 0.28] or Drug × Group interaction 
[F(10,105) = 1.65, P = 0.103, MSE = 0.007]. Follow-up anal-
ysis for the main effect of Drug indicated that overall activity 
rates after 3 mg/kg nafadotride pretreatment was lower than sa-
line [LSDmmd = 0.048]. For individual groups, activity after 3 
Fig. 5. Panel A shows the mean dipper entry rates (± 1 S.E.M.) of 
MPEP substitution for each nicotine training group. Panel B shows 
the mean beam break (activity) rates (± 1 S.E.M.) of MPEP substitu-
tion for each nicotine training group. The number of rats for MPEP 
substitution was 9, 9, and 8 for the 0.1, 0.2, and 0.4 mg/kg groups, 
respectively. For both panels, signifi cant differences and baseline 
means are reported in the text.
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mg/kg nafadotride pretreatment was lower than saline pretreat-
ment only for the 0.4 mg/kg group [LSDmmd = 0.091]. 
Fig. 6C shows the mean dipper entry rates for responding on 
nicotine after pretreatment with MK-801. There was a main ef-
fect of Drug [F(3,63) = 18.63, P < 0.001], but no main effect of 
Group or Drug × Group interaction [Fs < 1, MSE = 0.002] in-
dicating that MK-801 decreased conditioned responding to nic-
otine regardless of training dose. For each training group, dip-
per entry rates after 0.1 mg/kg MK-801 pretreatment were low-
er than saline pretreatment [LSDmmd = 0.044]. The saline base-
line described for nafadotride was also used for MK-801. For 
all nicotine doses, conditioned responding was higher than the 
saline baseline with pretreatment of 0.01 and 0.03 mg/kg MK-
801 and saline. Only 0.1 mg/kg MK-801 lowered conditioned 
responding to baseline saline levels. ED50s for 0.1, 0.2, and 0.4 
mg/kg nicotine groups were 0.055, 0.052, and 0.060 mg/kg MK-
801, respectively. Activity after MK-801 pretreatment is shown 
in Fig. 6D. There was a signifi cant main effect of Drug [F(3,63) 
= 6.17, P = 0.001], but no main effect of Group [F(2,21) = 3.19, 
P = 0.063] or signifi cant Drug × Group interaction [F < 1, MSE 
= 0.008]. Activity was lower on sessions with 0.1 mg/kg MK-
801 pretreatment than saline only for the 0.2 mg/kg group [LS-
Dmmd = 0.089].
3.2.6. MK-801 antagonism (0.2 mg/kg)
This fi nal test was added to extend the observed effect 
of 0.1 mg/kg MK-801 to a higher dose. The bars in Fig. 6C 
show the dipper entry rates of 0.2 mg/kg MK-801 antago-
nism for each nicotine group. A 2-way ANOVA comparing 
responding on saline and MK-801 pretreatment revealed a 
main effect of Drug [F(1,17) = 16.64, P = 0.001], indicating 
that responding on 0.2 mg/kg MK-801 pretreatment was low-
er than on saline pretreatment, but did not reveal a main ef-
fect of Group or Drug × Group interaction [Fs < 1, MSE = 
0.005]. For the 0.1 and 0.4 mg/kg groups, responding on 0.2 
mg/kg MK-801 was lower than saline pretreatment [LSDmmd 
= 0.081]. There was no difference in dipper entries for the 0.2 
mg/kg group. Of the 7 rats in the 0.2 mg/kg nicotine group, a 
single rat scored more than twice as high as any of the other 
rats in the condition, causing the lack of difference. Addition-
ally, for all 3 training groups, dipper entry rates on 0.2 mg/kg 
MK-801 was the same as the respective saline baselines and 
responding following saline pretreatment was higher than the 
saline baselines. Fig. 6D includes the activity rates for the 0.2 
mg/kg MK-801 antagonism test. There were no main effects 
of Drug or Group and no Drug × Group interaction [Fs < 1, 
MSE = 0.030], indicating that the blockade of conditioned re-
Fig. 6. Panel A shows the mean dipper entry rates (± 1 S.E.M.) of nafadotride antagonism for each nicotine training group. Panel B shows the 
mean beam break (activity) rates (± 1 S.E.M.) of nafadotride antagonism for each nicotine training group. Panel C shows the mean dipper en-
try rates (± or + 1 S.E.M.) of MK-801 antagonism for each nicotine training group. Panel D shows the mean beam break (activity) rates (± or + 
1 S.E.M.) of MK-801 antagonism for each nicotine training group. The number of rats for nafadotride and MK-801 antagonism was 8, 9, and 
7 for the 0.1, 0.2, and 0.4 mg/kg groups, respectively. The 0.2 mg/kg MK-801 dose is separated from the graphs in panels C and D to represent 
the procedural separation for testing. The number of rats for the 0.2 mg/kg MK-801 antagonism test was 7, 7, and 6 for the 0.1, 0.2, and 0.4 mg/
kg groups, respectively. For all panels, signifi cant differences, ED50s, and baseline means are reported in the text. 
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sponding by 0.2 mg/kg MK-801 pretreatment was not due to 
a general decrease in activity.
3.2.7. Nafadotride substitution
Tests of nafadotride substitution were conducted because 
early results from the nafadotride antagonism phase showed a 
pattern of increased chamber activity that diminished with con-
tinued testing. A rat from the 0.1 mg/kg nicotine group was re-
moved during this portion of the study for failure to eat, and 2 
rats from the 0.2 and 1 rat from the 0.4 mg/kg group were re-
moved due to an inability to continue to test, leaving 7, 7, and 
6 rats for groups 0.1, 0.2, and 0.4 mg/kg nicotine, respective-
ly. Fig. 7A shows dipper entry rates for nafadotride substitution. 
Although there was no main effect of Drug [F(5,85) = 1.45, P = 
0.214] or Drug × Group interaction [F(10,85) = 1.41, P = 0.188, 
MSE < 0.001], there was a signifi cant main effect of Group 
[F(2,17) = 3.79, P = 0.044, MSE = 0.004]. The 0.1 and 0.2 mg/
kg groups had lower overall dipper entry rates than the 0.4 mg/
kg group [LSDmmd = 0.029; Ms = 0.038, 0.031, and 0.066 for 
the 0.1, 0.2, and 0.4 mg/kg groups, respectively]. Activity rates 
for nafadotride substitution are shown in Fig. 7B. There was no 
effect of Drug [F < 1], but there was a signifi cant main effect of 
Group [F(2,17) = 4.72, P = 0.024] and a Drug × Group interac-
tion [F(10,85) = 2.05, P = 0.038]. Overall, there was no differ-
ence in activity between the 0.1 and 0.2 mg/kg group, and the 
0.4 mg/kg group had higher activity rates than 0.1 and 0.2 mg/
kg groups [LSDmmd = 0.072]. For the 0.1 and 0.4 mg/kg groups, 
there were no differences between all tested doses of nafado-
tride and saline [LSDmmd = 0.091]. For the 0.2 mg/kg group, 0.1 
mg/kg nafadotride decreased activity rates below that of saline. 
4. Discussion
Consistent with previous research, the 0.4 mg/kg nico-
tine group readily acquired conditioned responding for sucrose 
within 12 training sessions (Besheer et al., 2004, Bevins and 
Palmatier, 2004 and Wilkinson et al., 2006b). The present study 
also found that 0.1 and 0.2 mg/kg nicotine came to evoke ro-
bust conditioned responding at a similar rate. Our fi ndings are 
in contrast to drug discrimination literature using equivalent 
doses of nicotine as a discriminative stimulus. Each of these 3 
training doses has served as a discriminative stimulus for rats 
in a 2-lever operant drug discrimination task (Chance et al., 
1977, Desai et al., 2003, Gasior et al., 1999, Morrison and Ste-
phenson, 1969, Pratt et al., 1983 and Stolerman et al., 1997). In 
this task, completion of a response requirement on one lever re-
sults in reinforcement, whereas responses on the other lever re-
sult in no reinforcement (Gasior et al., 2000, Gasior et al., 2002, 
Morrison and Stephenson, 1969, Pratt et al., 1983, Stolerman, 
1989 and Stolerman et al., 1984). On intermixed vehicle ses-
sions, responding on the opposite lever is reinforced. When 0.1 
mg/kg nicotine is used as the discriminative stimulus (i.e., not 
faded from 0.4 mg/kg nicotine), acquisition can take much lon-
ger than higher nicotine doses (Chance et al., 1977 and Gasi-
or et al., 1999). For example, rats trained on 0.4 mg/kg nicotine 
required 28 to 43 training days before meeting criteria for sta-
ble discrimination performance, whereas rats trained on 0.1 mg/
kg nicotine required 38 to 94 training days before meeting the 
same criteria (Gasior et al., 1999).
The similar acquisition rate in the current study might lead 
one to conclude that 0.1 mg/kg nicotine is as salient as the high-
er nicotine doses (for discussions of effects of conditional stim-
ulus salience on acquisition of Pavlovian conditioning, see Frey 
and Sears, 1978, Pavlov, 1927, Rescorla, 1988 and Rescorla and 
Wagner, 1972). A non-salience explanation for the similar ac-
quisition rate of the 3 groups (0.1, 0.2, and 0.4 mg/kg) involves 
the rich schedule of sucrose deliveries in nicotine sessions. 
Wilkinson et al. (2006b) used different unconditioned stimulus 
densities to examine acquisition of conditioned responding with 
a 0.4 mg/kg nicotine conditional stimulus. The highest uncondi-
tioned stimulus density in that study, 36 intermittent sucrose de-
liveries over 20-min nicotine sessions, resulted in robust con-
ditioned responding that was acquired within 10 training ses-
sions; acquisition took longer in groups trained with fewer su-
crose deliveries per session. Because 0.1 and 0.2 mg/kg nico-
tine had not previously been trained as conditional stimuli, the 
current research used 36 deliveries of sucrose in order to maxi-
mize the chances of observing conditioning. The possibility ex-
ists that with this many nicotine-sucrose pairings, even a nico-
tine dose that would otherwise have been a weaker condition-
al stimulus could come to be a strong conditioned exciter. Our 
measure of conditioned responding comes from the early por-
Fig. 7. Panel A shows the mean dipper entry rates (± 1 S.E.M.) of na-
fadotride substitution for each nicotine training group. Panel B shows 
the mean beam break (activity) rates (± 1 S.E.M.) of nafadotride sub-
stitution for each nicotine training group. The number of rats for na-
fadotride substitution was 7, 7, and 6 for the 0.1, 0.2, and 0.4 mg/
kg groups, respectively. For both panels, signifi cant differences and 
baseline means are reported in the text. 
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tion of each conditioning session before any sucrose is deliv-
ered. If we could measure conditioned responding after every 
few nicotine-sucrose pairings, differences in acquisition as a 
function of training dose may have emerged.
In the present study, the 3 nicotine training groups showed 
decreases in conditioned responding as nicotine test doses were 
shifted away from the training dose with the exception of the 
0.4 mg/kg trained group when tested with 0.2 mg/kg (see be-
low). The ED50s were similar across groups (0.054, 0.049, and 
0.050 mg/kg for 0.1, 0.2, and 0.4 mg/kg groups, respective-
ly); a fi nding consistent with the similarities in acquisition rate 
and magnitude of conditioned responding across training doses. 
Besheer et al. (2004) found an ED50 of 0.113 mg/kg for a group 
trained on 0.4 mg/kg nicotine. In that study, sucrose was deliv-
ered only 8 times on nicotine sessions, whereas in the current 
research, sucrose was delivered 36 times. This difference sug-
gests that after the greater number of nicotine-sucrose pairings, 
less nicotine was necessary to prompt conditioned responding. 
When different nicotine training doses are used in the operant 
drug discrimination literature, results are mixed as to whether 
rats trained on low doses of nicotine are more sensitive to the 
cueing effects of nicotine compared with rats trained on high-
er doses of nicotine. In several papers, rats trained on 0.1 mg/
kg nicotine tended to have lower ED50s (e.g., 0.026 mg/kg for 
Chance et al., 1977; 0.024 mg/kg for Desai et al., 2003; 0.02 
mg/kg for Stolerman et al., 1997) than rats trained on 0.4 mg/
kg nicotine (e.g., 0.087 mg/kg for Chance et al., 1977; 0.09 mg/
kg for Gasior et al., 2002; 0.14 mg/kg for Pratt et al., 1983). 
However, this difference is not always observed. Gasior et al. 
(1999) found that ED50s did not differ between 0.1 and 0.4 mg/
kg groups (0.049 and 0.05 mg/kg, respectively).
Notably, in the present study, rats trained on 0.4 mg/kg nico-
tine increased responding when tested with the 0.2 mg/kg dose. 
A similar pattern did not occur with the other training doses. 
This increase in conditioned responding to a lower dose than 
the 0.4 mg/kg training dose was a non-signifi cant trend in the 
Besheer et al. (2004) study in which rats received 8 deliver-
ies of sucrose on nicotine sessions rather than the 36 deliveries 
used in the present study. Additionally, ongoing research in our 
laboratory using 36 deliveries of sucrose on nicotine sessions is 
replicating this effect. Further, a similar trend was also report-
ed by Pratt et al. (1983) in a 2-lever operant drug discrimination 
task. We believe the increased responding at the lower test dose 
in our study indicates that expression of conditioned responding 
is slightly attenuated by an early inhibitory effect of the 0.4 mg/
kg training dose. The exact nature of this inhibitory effect, how-
ever, will require further elucidation (see later discussion of ac-
tivity with MPEP antagonism).
Besheer et al. (2004) found that the 0.4 mg/kg nicotine con-
ditional stimulus was antagonized by the central and periph-
eral nicotinic acetylcholine receptor channel-blocking antag-
onist mecamylamine (Papke et al., 2001), and not by the pre-
dominately peripheral nicotinic acetylcholine receptor antago-
nist hexamethonium (Asghar and Roth, 1971), indicating that 
the cueing effects of nicotine were centrally mediated. Nicotin-
ic acetylcholine receptors mediate release of both dopamine and 
glutamate in the mesocorticolimbic region of the brain (Pontieri 
et al., 1996 and Schilström et al., 2003). Taken together, the re-
sults of the current research suggest that there is minimal infl u-
ence of dopamine D1, D2, or D3 receptors in the nicotine con-
ditional stimulus. The dopamine D1 and D2/3 receptor antago-
nists, SCH-23390 and eticlopride, respectively, decreased con-
ditioned responding regardless of nicotine training dose. This 
decrease in conditioned responding, however, coincided with 
a decrease in general chamber activity, indicating non-spe-
cifi c effects of the antagonists. Although this data pattern pre-
cludes us from concluding that dopamine D1 or D2/3 receptors 
are involved in the conditional stimulus effects of nicotine in 
the present study, it does not eliminate the possibility that oth-
er available antagonists for these receptors could block condi-
tioned responding without affecting activity. Albeit less pro-
nounced, there was a similar decrease in activity and condi-
tioned responding for dopamine D3 receptor antagonism with 
nafadotride in the 0.4 mg/kg nicotine group. Because we want-
ed to parse apart the potential dopamine D2 and D3 receptor ef-
fects, we did not use doses higher than 3 mg/kg nafadotride. In 
male Sprague-Dawley rats, doses higher than 3 mg/kg cause a 
loss of dopamine D3 receptor specifi city due to increased dopa-
mine D2 receptor binding (Audinot et al., 1998 and Levant and 
Vansell, 1997). These fi ndings are similar to operant drug dis-
crimination work in which dopamine has a minimal role in the 
function of nicotine as a discriminative stimulus (Corrigall and 
Coen, 1994, Le Foll et al., 2005, Mansbach et al., 1998, Reavill 
and Stolerman, 1987 and Shoaib, 1998).
Previous research with nafadotride has shown that the antag-
onist is behaviorally active when administered on its own to rats 
(e.g., Gyertyán and Sághy, 2004, Kuballa et al., 2005 and Sautel 
et al., 1995). There are mixed reports as to whether nafadotride 
doses lower than 3 mg/kg increase spontaneous locomotor activ-
ity in habituated rats (Gyertyán and Sághy, 2004 and Sautel et 
al., 1995). In the current research, when nafadotride was admin-
istered alone, activity was not increased above saline levels.
Nicotine administration also produces increased glutamate 
release throughout the striatum (McGehee et al., 1995, Schil-
ström et al., 2000, Schilström et al., 2003 and Toth et al., 1993), 
allowing for the potential of glutamatergic mediation of the con-
ditional stimulus properties of nicotine. To our knowledge, only 
one study has examined the effects of MPEP, an mGluR5 an-
tagonist, on the nicotine discriminative stimulus. In that study, 
Zakharova et al. (2005) assessed whether pretreatment with 5.6 
mg/kg MPEP shifted the nicotine dose-effect function for rats 
trained with 0.6 mg base/kg nicotine. They found that MPEP 
partially blocked the nicotine cue only at doses lower than the 
training dose of nicotine, demonstrating a marginal role for 
metabotropic glutamate receptor type 5 activation in nicotine 
drug discrimination. Similarly, in the current research, 1 mg/kg 
MPEP partially blocked dipper entries in the 0.1 mg/kg nico-
tine group without reducing general chamber activity. All other 
decreases in conditioned responding coincided with a reduction 
in general activity, indicating non-specifi c effects of MPEP. As 
noted earlier, such a pattern complicates interpretation of MPEP 
antagonism of goal tracking.
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Interestingly, we found an increase in general activity for 
the 0.4 mg/kg nicotine group when pretreated with 0.3 and 1 
mg/kg MPEP. The increase did not occur in the 0.1 or 0.2 mg/
kg nicotine groups. MPEP administration alone did not in-
crease chamber activity; therefore, this effect is not due to a 
summation of the locomotor activating effects of 0.4 mg/kg 
nicotine with MPEP. There is the possibility that the co-ad-
ministration of nicotine with the low doses of MPEP may be 
antagonizing some inhibitory component of the 0.4 mg/kg 
nicotine dose, allowing for increased activity. Because the 
increase in activity was not paralleled by a change in con-
ditioned responding, MPEP did not alter the nicotine cue at 
those doses, suggesting that the antagonized component of 
nicotine administration was specifi c to general chamber activ-
ity. Because MPEP did not increase conditioned responding, 
the proposed explanation is somewhat at odds with the nico-
tine generalization results described previously in which rats 
trained with the 0.4 mg/kg dose displayed an increase in con-
ditioned responding when tested with 0.2 mg/kg. Although we 
do not have activity data for the generalization portion of the 
current study, ongoing research in our laboratory shows that 
0.4 mg/kg trained rats do not show increased activity when 
tested with 0.2 mg/kg nicotine. Enhancement of locomotor ac-
tivity has also been demonstrated when MPEP is co-admin-
istered with phencyclidine, an N-methyl-D-aspartate receptor 
channel blocker (Henry et al., 2002, Kinney et al., 2003, Pi-
etraszek et al., 2004 and Snell and Johnson, 1986) but not am-
phetamine (Pietraszek et al., 2004). The current research ex-
tends this observation to 0.4 mg/kg nicotine, suggesting a 
possible shared mechanism of N-methyl-D-aspartate receptor 
blockade and nicotinic acetylcholine receptor activation that 
is enhanced by MPEP. The 0.1 and 0.2 mg/kg nicotine trained 
rats did not show this effect of MPEP pretreatment indicating 
that 0.4 mg/kg nicotine may have somewhat different cellular 
processes than the lower doses. Further research into the lo-
comotor enhancing effects of metabotropic glutamate recep-
tor type 5 blockade is necessary before any conclusions can be 
drawn concerning MPEP-nicotine interactions.
In the present study, MK-801 pretreatment resulted in de-
creased conditioned responding evoked by nicotine without a 
corresponding decrease in general chamber activity, implicating 
N-methyl-D-aspartate receptors in the conditional stimulus ef-
fects of nicotine. Before this conclusion can be accepted, sever-
al alternative explanations for the behavioral effects of MK-801 
must be addressed. One possible mechanism by which MK-801 
may exert its effect on conditioned responding is that N-meth-
yl-D-aspartate receptor activation may be necessary for retrieval 
of the neural representation of a nicotine cue. Another possible 
explanation is that the co-administration of MK-801 with nico-
tine may create a drug state that is different from that in which 
the nicotine-sucrose association was learned (see Tzschentke 
and Schmidt, 2000; see also Wolf, 1998). For this latter possi-
bility, MK-801 has served as an effective discriminative stimu-
lus in operant drug discrimination work (Corbett, 1995, Smith 
et al., 1999 and Zajaczkowski et al., 1996), and therefore, in 
our study, the addition of MK-801 to nicotine may be creating 
a distinct cue different from that of nicotine alone. These two 
alternative accounts, however, are strained by the recent fi nd-
ing that MK-801 did not block nicotine-appropriate responding 
in the Zakharova et al. (2005) study using a 2-lever drug dis-
crimination task. If MK-801 was blocking retrieval or creating 
a distinct drug state when combined with nicotine, these authors 
should have observed less responding on the nicotine-appropri-
ate lever. Although the training dose of nicotine in that study 
(0.6 mg/kg) was markedly higher than any used in the current 
research (0.1-0.4 mg/kg), the dose of MK-801 was also much 
higher (up to 0.6 mg/kg).
MK-801 also acts as a nicotinic acetylcholine receptor 
channel blocker (Amador and Dani, 1991, Buisson and Ber-
trand, 1998 and Ramoa et al., 1990) and could be producing 
the decrease in conditioned responding via that mechanism. 
Because the nicotine conditional stimulus has been blocked 
by mecamylamine (Besheer et al., 2004), the effects of MK-
801 pretreatment are consistent with previous fi ndings and al-
low for the potential of nicotinic acetylcholine receptor ac-
tion of MK-801 in the current research. This action of MK-
801 in a behavioral paradigm is highly unlikely, however, as 
MK-801 has a 40- to 100-fold selectivity for N-methyl-D-as-
partate receptors over nicotinic acetylcholine receptors (Ama-
dor and Dani, 1991, Huettner and Bean, 1988 and Löscher et 
al., 2003). The possibility is further strained by the fi nding 
that there is a demonstrated difference between the abilities of 
MK-801 and mecamylamine to disrupt behavioral effects of 
nicotine (Zakharova et al., 2005).
Nicotine has been previously established to have associa-
tive properties beyond that of an unconditioned stimulus or re-
inforcer (Besheer et al., 2004, Bevins and Palmatier, 2004 and 
Wilkinson et al., 2006b). The current study further character-
ized the conditional stimulus properties of nicotine by show-
ing that a dose of nicotine that has limited unconditioned effects 
(cf. Bevins and Palmatier, 2003, Bevins et al., 2001 and Iwamo-
to and Williamson, 1984) readily serves as robust conditional 
stimulus. Additionally, the current study shows the fi rst exam-
ple of a pharmacological dissociation between the roles of nico-
tine as a discriminative stimulus versus nicotine as a condition-
al stimulus. N-methyl-D-aspartate receptor antagonism by MK-
801 blocked the nicotine cue in the present appetitive Pavlov-
ian drug discrimination task but has not blocked the nicotine 
cue in an operant drug discrimination paradigm (Zakharova et 
al., 2005), indicating that activation of N-methyl-D-aspartate re-
ceptors may be a component of what allows nicotine to func-
tion as a conditional stimulus. Although caution must be tak-
en when making direct comparisons between studies using dif-
ferent training and test doses of drugs, it is clear that the disso-
ciation highlights the potential for mechanistic differences be-
tween the types of nicotine cues. This fi nding also suggests that 
not only are there associative properties underlying human to-
bacco use beyond the current conceptualization, but that there 
may be additional pharmacological components that contribute 
to the prevalence of worldwide nicotine consumption that have 
yet to be fully explored (Bevins and Palmatier, 2004 and Mack-
ay and Eriksen, 2002). 
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